Patients suffering from drug-resistant tuberculosis may soon have access to Delamanid, one of two new drugs to get approval for the treatment of tuberculosis after more than 40 years. The drug was added to the kitty shrinking choices to treat multi-drug resistant (MDR) and resistant to resistant tuberculosis (XDR) shortly after bedaquiline.
The study examined drug resistance models of 13 TB.
The head of the Indian Medical Research Council (ICMR) Dr. Soumya Swaminathan said that the manufacturer of the drug has applied with the DCGI.
"The drug is not yet licensed in India, we will probably follow the same path as bedaquiline, which is a conditional approval. It will only be allowed in programmes and may not get marketing authorisation," she said Delamanide, known for its new mechanism of fight against bacteria, has shown good results in the treatment of tuberculosis
Meanwhile, the results of the first national survey on drug resistance should be made public before World TB Day on 24 March
